Individual Patient Compassionate Use of Mirdametinib

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Inclusion Criteria:

• Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted.
• Patient does not qualify to participate in an ongoing clinical trial.